{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:58:06Z","timestamp":1776866286426,"version":"3.51.2"},"reference-count":51,"publisher":"SLACK, Inc.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Ann"],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>CME Educational Objectives<\/jats:title>\n                    <jats:list list-type=\"order\">\n                      <jats:list-item>\n                        <jats:label>1.<\/jats:label>\n                        <jats:p>Review the current epidemiology of meningococcal disease in children.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:label>2.<\/jats:label>\n                        <jats:p>Discuss the history of meningococcal vaccine development and the unique challenges posed by developing a vaccine against this microbe.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:label>3.<\/jats:label>\n                        <jats:p>Determine vaccine recommendations as well as potential roadblocks to routine vaccination of young children.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The spectrum of disease caused by\n                      <jats:italic toggle=\"yes\">Neisseria meningitidis<\/jats:italic>\n                      includes bacteremia, fulminant sepsis (meningococcemia), meningitis, and pneumonia. The incidence of meningococcal infection has long been higher in infancy than adolescents or adults older than 65 years (a third group with an increased risk based on age). Five meningococcal serogroups (A, B, C, Y, and W135) cause the great majority of human disease. Serogroup B strains cause about two-thirds of disease in children younger than 6 years. For this reason, new meningococcal vaccine formulations have been developed and evaluated in children younger than 2 years.\n                    <\/jats:p>\n                    <jats:p>Of four meningococcal vaccines currently licensed in the United States, two conjugate products, (MenACWY-D [Menactra], Sanofi Pasteur; HibMenCY-TT [MenHibrix], GlaxoSmithKline), are recommended for infants and toddlers younger than 2 years who have an increased risk for invasive meningococcal disease. High-risk conditions are complement deficiencies, community outbreaks, functional or anatomic asplenia, and travel to high-risk areas in which serogroup A infection is prevalent. Recommendations vary by age, dosing, and indication between these two products. Both licensed products are immunogenic and have side-effect profiles that are considered safe for use. In most cases, concomitant use with other recommended childhood vaccines does not interfere with responses to these vaccines.<\/jats:p>\n                    <jats:p>\n                      As of yet, there has not been universal adoption of this immunization in the infant population by parents or providers. Factors that weigh against the implementation of a national routine infant program include the prevention of only 40 to 50 meningococcal cases, two to four deaths per year, and a relatively low case fatality among infants. Some argue that costs should not be considered a barrier because infant deaths and morbidity would be prevented. The availability of a serogroup B vaccine would improve impact and cost-effectiveness of a routine infant meningococcal vaccine program. Debate over the implementation of routine infant meningococcal vaccination in the United States is ongoing. This review focuses on vaccines for the prevention of\n                      <jats:italic toggle=\"yes\">N. meningitidis<\/jats:italic>\n                      infection in infants and young toddlers in the first 2 years of life.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/00904481-20130723-11","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T15:55:48Z","timestamp":1408463748000},"source":"Crossref","is-referenced-by-count":6,"title":["Prevention of Meningococcal Infections in the First 2 Years of Life"],"prefix":"10.3928","volume":"42","author":[{"given":"Charles R.","family":"Woods","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1210"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.070"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.061"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/649209"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181d3ce32"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70251-6"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(81)80250-8"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199611000-00009"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0281"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70180-1"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.10.008"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-2575"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2012.02687.x"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1327"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.051"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-1-200901060-00009"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.04.013"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165-Supplement_1-S49"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2006.00051.x"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/140.5.690"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00299-7"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318282942f"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/648966"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.10.005"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/656741"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/15459620802003896"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2011.02.007"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/527401"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir466"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.026"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819040e7"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/509619"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir198"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31823e1e34"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181fcb2bf"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318268dfe4"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","unstructured":"US Food and Drug Administration. Highlights of Prescribing Information for Menactra (package insert). Available at: www.fda.gov\/downloads\/BiologicalsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM131170.pdf. Accessed June 26 2013.10.1177\/1942602X12455247","DOI":"10.1177\/1942602X12455247"},{"key":"e_1_3_1_41_2","unstructured":"US Food and Drug Administration. Highlights of Prescribing Information for Menhibrix (package insert). Available at: www.fda.gov\/downloads\/BiologicalsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM308577.pdf. Accessed June 26 2013."},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.90"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-2992"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.2.14170"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.20357"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2007.29-c"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31823dce5c"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0848-8"},{"key":"e_1_3_1_49_2","unstructured":"Centers for Disease Control and Prevention. CDC Health Information for International Travel 2012. New York: Oxford University Press; 2012. Available at: wwwnc.cdc.gov\/travel\/yellowbook\/2012\/chapter-7-international-travel-infants-children\/vaccine-recommendations-for-infants-and-children.htm. Accessed June 26 2013."},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182840e35"},{"key":"e_1_3_1_51_2","unstructured":"Meissner HC. Meningococcal Vaccines Work Group Update Advisory Committee on Immunization Practices meeting June 20 2012. Available at: www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-jun-2012\/01-MCV-Meissner.pdf. Accessed June 26 2013."},{"key":"e_1_3_1_52_2","volume-title":"Paper presented at: Pediatric Academic Societies Annual Meeting","author":"Danoff G","unstructured":"Danoff G, Plotkin S. Should routine meningococcal immunization of infants be implemented? Pediatric Infectious Diseases Society Symposium (1630A). Paper presented at: Pediatric Academic Societies Annual Meeting; May 04, 2013; Washington, DC."}],"container-title":["Pediatric Annals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/00904481-20130723-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:10:13Z","timestamp":1776863413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/00904481-20130723-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8,1]]}},"alternative-id":["10.3928\/00904481-20130723-11"],"URL":"https:\/\/doi.org\/10.3928\/00904481-20130723-11","relation":{},"ISSN":["0090-4481","1938-2359"],"issn-type":[{"value":"0090-4481","type":"print"},{"value":"1938-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,1]]}}}